Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancerMasato Karayama, Takafumi Suda|Cancer Immunology Immunotherapy|2021Cited by 44
Evaluation of Programmed Death Ligand 1 (<i>PD-L1</i>) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung CancerYusuke Inoue, Takafumi Suda|JAMA Network Open|2020Cited by 35
Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapyYusuke Inoue, Takafumi Suda|Cancer Immunology Immunotherapy|2023Cited by 14
Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomasDaisuke Akahori, Takafumi Suda|Scientific Reports|2021Cited by 9